Ursodeoxycholic acid (UDCA) is used to treat biliary disorders; and, bile acids alter mast cell (MC) histamine release. MCs infiltrate Mdr2 −/− mice liver (model of primary sclerosing cholangitis (PSC)). MC-derived histamine increases inflammation, hepatic stellate cell (HSC) activation and fibrosis. The objective was to determine the effects of UDCA treatment on MC infiltration, biliary damage, inflammation and fibrosis in Mdr2 −/− mice and human PSC. Wild-type and Mdr2 −/− mice were fed bile acid control diet or UDCA (0.5% wt/wt). Human samples were collected from control and PSC patients treated with placebo or UDCA (15 mg/kg/BW). MC infiltration was measured by immunhistochemistry and quantitative polymerase chain reaction (qPCR) for c-Kit, chymase, and tryptase. The HDC/histamine/histamine receptor (HR)-axis was evaluated by EIA and qPCR. Intrahepatic bile duct mass (IBDM) and biliary proliferation was evaluated by CK-19 and Ki-67 staining. Fibrosis was detected by immunostaining and qPCR for fibrotic markers. Inflammatory components were measured by qPCR. HSC activation was measured by SYP-9 staining. Inflammation was detected by qPCR for CD68. In vitro, MCs were treated with UDCA (40 μM) prior to HA secretion evaluation and coculturing with cholangiocytes or HSCs. BrDU incorporation and fibrosis by qPCR was performed. UDCA reduced MC number, the HDC/ histamine/HR-axis, IBDM, HSC activation, inflammation, and fibrosis in Mdr2 −/− mice and PSC patients. In vitro, UDCA decreases MC-histamine release, which was restored by blocking ASBT and FXRβ. Proliferation and fibrosis decreased after treatment with UDCA-treated MCs. We conclude that UDCA acts on MCs reducing histamine levels and decreases the inflammatory/hyperplastic/fibrotic reaction seen in PSC. Ursodeoxycholic acid (UDCA) is used to treat biliary disorders; and, bile acids alter mast cell (MC) histamine release. Following liver injury like primary sclerosing cholangitis in mice and humans, MCs infiltrate. MC-derived histamine increases biliary damage, fibrosis, and inflammation. UDCA treatment decreases these parameters via reduced MC activation.
Introduction
Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that damages bile ducts inside and outside the liver. During PSC, bile ducts are inflamed, which leads to scarring and narrowing resulting in fibrosis and cirrhosis of the liver and, eventually, liver failure [1] . The only definitive treatment to date is liver transplantation [1, 2] . Multidrug resistance-2 gene knockout mice (Mdr2 −/− ) develop spontaneous liver fibrosis and mimic some features of human PSC [3, 4] . Mdr2 −/− mice have enhanced intrahepatic bile duct mass (IBDM), biliary proliferation and hepatic fibrosis between 4 and 12 weeks of age [4, 5] .
Within MCs are intact granules that carry inflammatory mediators like histamine and various cytokines and chemokines [6] [7] [8] . MCs infiltrate the liver upon damage, surround bile ducts increasing local histamine levels and enhance biliary mass, proliferation, and hepatic fibrosis [5, 9] . In our previous work, we demonstrated that, in bile ductligated (BDL) rats and Mdr2 −/− mice treated with the MC stabilizer, cromolyn sodium, there is reduced biliary damage and liver fibrosis [5, 9] . In MC-deficient mice, IBDM and hepatic fibrosis are reduced following BDL compared to WT BDL mice [10] . In addition, when MCdeficient mice were injected with cultured MCs, these parameters increased demonstrating that MCs regulate biliary injury and hepatic fibrosis [10] .
Ursodeoxycholic acid (UDCA) is a natural bile acid that forms about 1-3% of total bile acids in human bile [11] . To date, UDCA (13-15 mg/kg/day) is the choice treatment for primary biliary cholangitis (PBC) patients that have abnormal liver enzymes; however, the role of UDCA in PSC has remained elusive and conflicting [11] . In fact, at high doses (28-30 mg/kg/day) UDCA can be harmful to PSC patients and studies to demonstrate effectiveness at lower doses are inconclusive [1] . UDCA exerts its anticholestatic effects by lowering serum liver enzymes, improving histology and increasing nontoxic bile acid pools, thus delaying the progression to liver transplant [2, 12, 13] . UDCA has been shown to regulate inflammatory cytokine release during cholestatic liver injury [14] . According to the 2009 European Association for the Study of Liver Disease (EASL), UDCA is an approved therapy for PSC patients and numerous patients are prescribed UDCA to ameliorate uncomfortable side effects [15] . The purpose of our study is to understand if UDCA acts on MCs or induces a synergistic interaction between MCs, cholangiocytes and hepatic stellate cells. Since it is unknown if UDCA interacts with MCs to alter PSC progression, we aimed to studied these parameters in both Mdr2 −/− mice and human PSC.
Method and materials

Reagents and other materials
Chemical grade reagents were purchased from Sigma-Aldrich Co (St. Louis, MO) unless stated otherwise. All mouse and human primers and real-time PCR materials were obtained from Qiagen (Fredrick, MD). Antibodies for immunohistochemistry and immunofluorescence were purchased from Abcam (Cambridge, MA) or Santa Cruz (Dallas, TX). Histamine EIA kits were purchased from Cayman Chemical (An Arbor, MI) [5, 9, 10] . The apical sodium-bile acid transporter inhibitor was obtained from Tocris Bioscience (Minneapolis, MN) and the farnesoid X receptor (FXRβ) inhibitor was obtained from Sigma-Aldrich Co (St. Louis, MO). Kits to measure total bile acids (TBAs) were purchased from Crystal Chemical, Inc (Downers Grove, IL) [5] .
In vivo models
We used the genetically modified mouse model of PSC, Mdr2 −/− mice on FVB/NJ background (wild-type, WT) [3, 5] . All mice were housed in the Baylor Scott and White Health Animal Facility and given free access to drinking water and standard chow. All animals were kept in a temperature-controlled environment with a 12:12 light/dark cycle, and all protocols strictly adhered to regulations as set forth by the local IACUC committee. Male mice (9-11 weeks of age) were fed a bile acid control diet (BAC, which contains the same components as the UDCA chow minus the bile acids)-or UDCA-enriched diet (0.5% wt/ wt) [16] for 1 week (10-12 mice per group). Diets were obtained from Dyets, Inc. (Bethlehem, PA) and from all animals we collected serum, isolated cholangiocytes (as previously described [5, 10, 17] ) and supernatants (collected after 4-6 h of incubation at 37° [5, 9, 10] ) and liver blocks (frozen and paraffin-embedded). We performed hematoxylin and eosin (H&E) staining in livers to evaluate lobular damage, hepatic necrosis and inflammation. TBAs were measured in serum and/or snap liver as previously described [5] .
Human PSC sampling
Human liver sections from normal controls (collected as part of liver cholangiocarcinoma resection and considered nondiseased areas) and PSC patients treated with placebo or UDCA (15 mg/kg/BW) were utilized (Supplementary Table 1 ). PSC patients presented with a range of early to late PSC as described in our previous work [5] . Liver sections (4-5 μm thick) obtained by needle biopsies from three control patients, three early stage PSC (with or without cirrhosis) and three early stage PSC patients treated with UDCA (with or without cirrhosis). The deidentified samples were provided by Dr. Pietro Invernizzi under a protocol approved by Humanitas Research Hospital; the protocol was approved by the Central Texas Veteran's Health Care System Institutional Review Board and Research Development Committee. Using acquired human tissue, H&E was performed to assess liver damage that was evaluated by a blinded pathologist; patient serum ALT levels were assessed via colorimetric analysis with an AbCam ALT kit (ab105134).
Detection of MCs, MC markers, HR, and histamine secretion
In all mice, MC presence was detected by immunohistochemistry in liver sections (4-5 μM thick) for mouse MC protease-1 (mMCP-1) and MC markers were measured in total liver by real-time PCR [9, 18] . The HDC/histamine receptor (HR)/HA-axis was measured by real-time PCR and by EIA from all groups of mice [17] . We measured MC number by toluidine blue staining in liver from normal rats fed either taurocholate (TC) or taurolithocholate (TLC) [19, 20] , and in BDL rats fed UDCA [21] .
We measured the expression of MC presence by immunohistochemistry for tryptase in human liver sections from control and PSC patients treated with placebo or UDCA. The gene expression of MC markers was also measured in these livers. H1-H4HR expression was measured by real-time PCR and histamine secretion was evaluated by EIA in serum from all patient groups.
Evaluation of biliary damage in Mdr2 −/− mice and hepatic fibrosis/HSC activation in mice and human PSC
In liver sections from all mice, we performed immunohistochemistry for the biliary marker, CK-19 [9, 17] to measure IBDM and Ki-67 [5] to detect the percentage of proliferating cholangiocytes as previously described by us. We measured fibrosis and HSC activation from all mice and human tissues as previously described by us [5, 9, 10] .
Fibrosis was assessed by Masson's Trichrome and Fast Green/Sirius Red (along with semiquantification) [17] . In total liver, we measured the following fibrotic markers by real-time PCR: collagen type-1a and fibronectin-1 [17] . TGF-β1 is a known regulator of HSC-driven fibrosis [5, 13] ; therefore, we measured TGF-β1 expression by realtime PCR in all groups of mice. To evaluate HSC activation, synaptophysin 9 (SYP-9) was measured by immunofluorescence in all mice groups co-stained with CK-19 to detect bile ducts [5, 10] . In human tissues, we measured the gene expression of fibronectin-1 [22, 23] and performed Masson's trichrome.
Measurement of the effects of UDCA treatment on inflammation and extracellular matrix proteins
We measured CD68 in our mouse tissues as an indicator of inflammatory response by real-time PCR. TNF-α is released from degranulated MC [18] ; therefore, we evaluated the expression of TNF-α in total liver from all mice by real-time PCR. We measured MMP-2, -3, and -9 by real-time PCR in total liver from WT, Mdr2 −/− + BAC and Mdr2 −/− + UDCA.
In vitro evaluation of MC/cholangiocyte/HSC interactions
To determine the direct effects of UDCA on (i) MC-derived histamine release and (ii) biliary and HSC response, we utilized cultured MCs, cholangiocytes, and human HSCs (hHSCs).
Cultured MCs were obtained from ATCC (Manassas, VA) and human HSCs from ScienCell, Carlsbad, CA. Murine cholangiocytes have previously been used by us and all cells were cultured according to previous protocols [5, 9, 10, 17] .
To determine how bile acids interact with MCs, we measured the expression of ASBT and FXRβ by immunofluorescence in cultured MCs. The ASBT antibody was a kind gift from Dr. Paul Dawson (Emory University School of Medicine) and FXRβ antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX).
To demonstrate that bile acid treatment alters MChistamine release, MCs were treated with UDCA (40 μM, 30-120 min) in the absence or presence of specific antagonists, guggulsterone (FXRβ inhibitor, 10 μM) and SC-435 (ASBT inhibitor, 100 nM) and histamine release was measured by EIA [10] . In separate experiments, MCs were treated with different bile acids including TC (40 μM, 24 h) and TLC (40 μM, 24 h) as well as UDCA (40 μM, 120 min); MC activation, MMP-2, -3, and -9 and TNF-α levels were evaluated by real-time PCR.
Next, cultured cholangiocytes or hHSCs were treated with 0.1% BSA (basal), MC supernatants (basal-treated) and MC supernatants collected following treatment with UDCA (40 μM, 120 min). Biliary proliferation was evaluated by BrDU staining and fibronectin-1 was measured by real-time PCR in treated HSCs [5, 10] . Biliary inflammation was measured by real-time PCR in treated cells for TNF-α, CCL-3, and IL-6.
In our final experiments, hHSCs were treated with 0.1% BSA (basal) or cholangiocyte supernatants collected from WT, Mdr2 −/− + BAC and Mdr2 −/− mice treated with UDCA. Following stimulation for 24 h, the expression of fibrosis markers including, TGF-β1, collagen type-1a and fibronectin-1 were evaluated by real-time PCR.
Statistical methods
All data is expressed as mean ± SEM. Groups were analyzed by the Student unpaired t test when two groups are analyzed or a two-way ANOVA when more than two groups are analyzed, followed by an appropriate post hoc test. p < 0.05 was considered significant.
Results
UDCA treatment ameliorates liver injury in Mdr2 −/− mice and human PSC
Extensive inflammation was found around bile ducts, which was ameliorated in Mdr2 −/− mice fed UDCA, which were similar to WT (Fig. 1a ). In Mdr2 −/− mice fed UDCA, total bile acid serum content decreased ( Fig. 1b ). According to pathology reports, the WT mouse liver has no significant histopathological findings; however, the Mdr2 −/− mouse fed BAC displays moderate to severe cholangitis with prominent duct obliteration and bridging fibrosis that is consistent with human PSC. Some bridging fibrosis and inactive hepatitis was also noted in the Mdr2 −/− mouse fed BAC. Finally, in the Mdr2 −/− mouse fed UDCA mild portal inflammation was detected along with minimal bridging fibrosis and mild cholangitis.
In human PSC, focal necrosis and inflammation increased compared to controls, which were decreased in PSC patients treated with UDCA ( Fig. 1c ). Further, serum ALT levels increased in PSC patients compared to controls and several patients treated with UDCA had decreased ALT levels, although not all patients responded to UDCA (Fig. 1d ). For H&E staining, the pathology reports indicate that there is mild steatohepatitis with limited fibrosis in the human control sample, whereas the PSC liver displays bile duct sclerosing cholangitis with bridging fibrosis and potential bile duct obstruction. The PSC patient treated with UDCA also displays mild sclerosing cholangitis; however, no evidence of obstruction was noted.
To correlate our findings with human dosing, we estimate that mice consumed a relative dose of 20-23 mg/kg BW per day. This calculation was based on the amount of UDCA in the diet, average weight of the mice, and average chow consumed per day. As stated, normal/low dose treatment is indicated at 13-15 mg/kg BW per day and higher doses are 28-30 mg/kg BW per day. Therefore, we are slightly over the range of the lower human dose, but we also recognize that there are multiple considerations that might alter our calculations including changes in appetite, which would influence the intake of the mouse.
UDCA treatment decreases MC presence/activation and inhibits the HDC/histamine/HR-axis in Mdr2 −/− mice and human PSC
In Mdr2 −/− mice, increased numbers of MCs (marked by red arrows) are found in close proximity to bile ducts. Further, UDCA treatment decreased MC number ( Fig. 2a) . Semiquantification of the average number of MCs is also shown. c-Kit, chymase and tryptase decreased in Mdr2 −/− mice fed UDCA ( Supplementary Fig. 2a ). In contrast, TC and TLC feeding increased MC number (marked by red arrows) in normal rats; whereas UDCA decreased MC number in rats subjected to BDL ( Supplementary Fig. 1A) .
Patients with advanced PSC display a robust infiltration of MCs (marked by red arrows) compared to control (similar to our previous work no MCs were detected in control [5] , data not shown) and, in patients with PSC treated with UDCA, there is a marked decrease in MC presence (Fig. 2b) . There is an upregulation of MC markers in livers from PSC patients treated with placebo, which are decreased in PSC patients treated with UDCA (Supplementary Fig. 1B) .
In Mdr2 −/− mice fed UDCA, the HDC/HR/HA-axis decreases (Figs. 3a and 4b ). The expression of H1-H4HR was upregulated in patients with PSC and treatment with UDCA decreased H2, H3, and H4HR (Fig. 3c) . We found increased serum histamine levels in PSC patients, whereas UDCA-treated PSC patients had reduced histamine levels (Fig. 3d ).
UDCA feeding ameliorates biliary hyperplasia, proliferation, hepatic fibrosis, inflammation, and HSC activation in Mdr2 −/− mice and human PSC We found that Mdr2 −/− mice fed UDCA have decreased IBDM (Fig. 4a ), biliary proliferation (Fig. 4b) , and collagen deposition/fibrosis (Fig. 5a, b ) compared to Mdr2 −/− mice fed BAC. Bridging fibrosis was increased in the Mdr2 −/− mouse fed BAC compared to WT and this was not as prominent in the Mdr2 −/− mouse fed UDCA. Activation of HSCs was determined by SYP-9 staining and we found an increase in qualitative SYP-9 expression in Mdr2 −/− mice fed BAC that was reduced in Mdr2 −/− mice fed UDCA (Fig. 5c ). Further, the expression of collagen type-1a, fibronectin-1 (Fig. 6a ) and SYP-9 ( Fig. 5c ) significantly decreased in Mdr2 −/− mice fed UDCA. Fig. 2 a Mast cell numbers are increased in Mdr2 −/− mice fed BAC compared to WT and UDCA feeding decreases the presence of mast cells shown by immunohistochemistry for mMCP-1 (marked by red arrows). Semiquantification demonstrates a significant increase in mast cell number in Mdr2 −/− mice fed BAC that is reduced in Mdr2 −/− mice fed UDCA. b By immunohistochemistry for tryptase there is an infiltration of mast cells found surrounding bile ducts in PSC patients treated with placebo compared to normal tissue that were void of mast cells (data not shown). In PSC patients treated with UDCA there were no visible mast cells surrounding the ducts. Images are 20× magnification CD68 expression increased in Mdr2 −/− mice fed BAC compared to WT and Mdr2 −/− mice fed UDCA had decreased expression ( Fig. 6b ). TGF-β and TNF-α gene expression increased in Mdr2 −/− + BAC mice compared to WT; and, when Mdr2 −/− mice were fed UDCA, TGF-β and TNF-α expression decreased (Fig. 6c, d ). Finally, we found that UDCA feeding decreased MMP-2, -3, and -9 in Mdr2 −/− mice compared to BAC feeding ( Supplementary  Fig. 3A) .
In human liver tissue fibronectin-1 expression increased in patients with PSC compared to control. UDCA treatment decreased this marker (Fig. 7a) . Further, Masson's trichrome staining revealed increased collagen deposition in PSC patients compared to control; that decreased in PSC patients treated with UDCA ( Fig. 7b ).
UDCA acts on MCs and alters biliary proliferation and HSC activation, in vitro
Cultured MCs express ASBT and FXRβ (Fig. 8a) . When MCs were treated with UDCA, histamine secretion significantly decreased and treatment with SC-435 (blocks ASBT) or gugglesterone (inhibits FXRβ) returned histamine secretion to normal levels (Fig. 8b) .
We found that UDCA decreased histamine secretion and the expression of c-Kit, tryptase and chymase (Fig. 9a, b) . In contrast, treatment with TC, but not TLC increased the expression of MC markers ( Supplementary Fig. 4A ).
Stimulation with basal-treated MCs induced biliary proliferation, whereas when cholangiocytes were treated with supernatant collected from MCs pretreated with UDCA ( Fig. 9c ), biliary proliferation decreased (Fig. 9d ). Similar to cholangiocytes, fibronectin-1 decreased in HSCs stimulated with UDCA-treated MC supernatants compared to MC basal treatments (Fig. 6e ). Further, in vitro, biliary inflammatory markers TNF-α, CCL-3, and IL-6 increased after stimulation with MC supernatants (basal-treated) and were reduced when cholangiocytes were stimulated with MC supernatants pretreated with UDCA ( Supplementary Fig. 5 ).
To demonstrate that MCs, cholangiocytes and HSCs work synergistically during PSC, cultured hHSCs stimulated with cholangiocyte supernatant from Mdr2 −/− mice fed BAC had increased TGF-β1, collagen type-1a and fibronectin-1 expression compared to either basal or Fig. 7 a The expression of fibronectin-1 was increased in total liver mRNA PSC patients compared to control and UDCA treatment decreased these fibrotic genes in PSC patients. b Masson's trichrome staining revealed increased collagen deposition in PSC patients compared to control and this was reduced in PSC patients treated with UDCA. Data are expressed as mean ± SEM of at least 12 experiments for PCR. * p < 0.05 vs. control. Images are 20× magnification treatment with WT cholangiocyte supernatants (Fig. 10a-c) . When hHSCs were stimulated with cholangiocyte supernatants from Mdr2 −/− mice fed UDCA, fibrotic markers significantly decreased (Fig. 10a-c) . Finally, in vitro UDCA decreased MC expression of MMP-2, -3, and -9 and TNF-α compared to basal treatment ( Supplementary Fig. 3B and C), whereas TC or TLC induced the expression of MMP-2, but not MMP-3 or MMP-9 ( Supplementary Fig. 4B ).
Discussion
MCs infiltrate Mdr2 −/− mice and human PSC; and, treatment with UDCA decreases MC activation coupled with reduced biliary damage, proliferation, inflammation and hepatic fibrosis. Further, we found that UDCA reduces histamine, TGF-β1 and inflammatory cytokine release from MCs thus reducing PSC-associated liver injury. In vitro, we found that MCs express specific bile acid transporters and nuclear receptors and inhibition of these components increases MC activity and subsequent histamine release. Further, cholangiocytes induce a response in HSC activity that can also be regulated by UDCA, in vitro.
We have previously reported that Mdr2 −/− mice and late stage PSC patients have increased MC numbers compared to controls [5] , and studies supporting our work show increased MC number and activation in cholangiocarcinoma, hepatocellular carcinoma, fatty liver disease and in hepatitis [24] [25] [26] . UDCA also decreases inflammatory MC number within gallbladders of patients with cholesterolinduced gallstones [27] . Further, we found that, in normal rats, TC and TLC increase MC number and in support of our findings, a study found that TC activates ileal secretion in WT mice via degranulation of MCs [28] .
Alpini et al. [21] reported that, in BDL rats, UDCA feeding decreased biliary mass, bile secretion, and cholangiocyte proliferation by activation of PKC-α. This was further investigated in BDL-vagotomized rats demonstrating that both UDCA and its taurine conjugate, TUDCA induced protective effects on the biliary tree via calciuminduced signaling [29] . While these studies support the concept that UDCA may reverse liver damage, Fickertt et al. [16] described that UDCA feeding exacerbates hepatic damage in Mdr2 −/− mice; however, these studies were performed in different aged mice (4 weeks of age) and there was no evaluation of biliary damage. It is important to note that we utilized 12 week old Mdr2 −/− mice that display a robust PSC phenotype when compared to earlier time points [16] .
Further, we found that UDCA decreases HSC activation, TGF-β1 and TNF-α expression coupled with inhibition of hepatic fibrosis. Our previous [5, 10] and current findings In support of this, in rats with CCl 4 -induced liver fibrosis, treatment with UDCA improved histopathological scores, decreased tissue hydroxyproline and inhibited MMP activation with overall amelioration of hepatic fibrosis [30] . Further, in nonalcoholic steatohepatitis, UDCA was found to be beneficial at repressing hepatic fibrosis and HSC activation by counteracting intestinal barrier dysfunction [31] . While the usage of UDCA for reducing fibrosis in PSC has been controversial, UDCA is useful in PBC management by decreasing inflammation and fibrosis [12] . Further, the derivative of UDCA, nor-UDCA, shows promising results in both animals and humans to reduce and ameliorate fibrosis in PSC and PBC [1, 2] .
MCs release numerous inflammatory mediators including histamine, TGF-β1 and TNF-α, all of which were reduced in Mdr2 −/− mice fed UDCA. During ulcerative colitis there is an increase in inflammatory cytokines, that are mostly ablated in MC-deficient rats [32] . Further, TNFα increases in lung tissues following autologous liver transplantation; however, when animals were treated with the MC stabilizers, cromolyn sodium, or ketotifen prior to transplantation, inflammatory mediators significantly reduced [33] . Additionally, BDL rats treated with UDCA displayed a significant decrease in TGF-β1 expression compared to control rats [34] and He et al. [35] found that the addition of retinoic acid to UDCA treatment decreased TGF-β1 and collagen deposition in BDL rats. The link between UDCA and inflammation has also been demonstrated in fatty liver disease. Pathil et al. [36] found that The expression of c-Kit, chymase, and tryptase decreased in mast cells treated with UDCA (40 μM, 120 min) shown by real-time PCR. c Mast cells were treated with 0.1% BSA (basal) or UDCA (40 μM, 120 min) and conditioned medium was collected. Cholangiocytes and HSCs were treated with conditioned medium and biliary proliferation and activation were measured. d In cholangiocytes treated with mast cell conditioned medium (basal) there was an increase in cholangiocyte proliferation shown by BrDU staining, whereas cholangiocyte proliferation decreased following treatment with conditioned medium from mast cells treated with UDCA. e HSCs stimulated with conditioned medium from basal-treated mast cells had increased expression of fibronectin-1, which was decreased in HSCs treated with conditioned medium from mast cells treated with UDCA. Data are expressed as mean ± SEM of at least 9 experiments for real-time PCR, 12 experiments for EIA and 10 experiments for BrDU labeling. * p < 0.05 vs. 0.1% BSA (basal); # p < 0.05 + MC (basal) treatment. Images are 20× magnification treatment with a conjugate of UDCA improved liver histology, steatosis and decreased proinflammatory cytokines in mice fed a high fat diet. In our study, we found that UDCA decreased MMP expression. Similar to this, it has been previously demonstrated that UDCA induced beneficial effects on liver ALT levels and inhibited MMPs leading to the destruction of extracellular matrix in the damaged liver [14] . Fig. 10 The expression of (a) collagen type-1a, (b) TGF-β1, and (c) fibronectin-1 were increased in hHSCs treated with cholangiocyte supernatant from Mdr2 −/− mice fed BAC compared to basal and WT supernatant treatments; however, expression of these fibrotic markers were decreased when hHSCs were stimulated with cholangiocyte supernatants from Mdr2 −/− mice fed UDCA. Data are expressed as mean ± SEM of at least six experiments for real-time PCR. * p < 0.05 vs. WT mice; # p < 0.05 vs. Mdr2 −/− mice fed BAC Further, patients treated with UDCA have decreased mast cell number, inhibited HA/HR axis, HSC activation and fibrosis and inflammation compared to placebo-treated patients. Finally, in vitro, UDCA acts on mast cells to decrease biliary proliferation and HSC activation Cholangiocytes express FXRβ and ASBT [37] . Similarly, we found that MCs express these components (along with others, data not shown) and may use these to allow UDCA (or other bile acids) to induce effects on MC degranulation. Whereas, UDCA has been demonstrated to be a weak ligand for FXR in some studies [38] , in our work, we found that blocking FXRβ restored MChistamine release (inhibited by UDCA treatment) suggesting that, in MCs, the UDCA/FXR interaction is important. Further, Mueller et al. [39] recently reported that UDCA exerts FXR antagonistic effects on patients with NAFLD. ASBT is a critical regulator of conjugated bile acids especially in cholangiocyte regulation [40, 41] and we demonstrated that inhibition of ASBT or FXR returns histamine levels back to normal following UDCA treatment. In support of our studies, it has been previously demonstrated that bile acids influence MC degranulation [42] and we found that UDCA decreases MC-histamine release, MC marker expression, biliary proliferation, and HSC activation, in vitro. Interestingly, a recent study has shown that the ASBT inhibitor itself may be a promising tool for reducing PSC progression and clinical trials are underway [43] . In this work the authors find that treatment with SC-435 decreases inflammation, damage and fibrosis in the Mdr2 −/− mouse model, which are interesting since we found that blocking ASBT returns histamine levels back to normal following UDCA treatment, in vitro. Considering that the authors used in vivo models and our studies on the ASBT inhibitor were in vitro, more experimental analysis should be performed to fully understand if ASBT alters MCs during disease progression.
In conclusion, our studies are the first to demonstrate that UDCA decreases MC number and histamine release, thereby inhibiting PSC-induced inflammation. Our novel data suggest an alternative strategy for UDCA action that also includes regulation of MC function (Fig. 11 ). Further studies are warranted to fully understand the implications of bile acid regulation on MC activation including determining the effects of nor UDCA, which has been shown to be a promising therapy for PSC patients [44] . Compliance with ethical standards
